Posted this on the other board. Just random specu
Post# of 72440
Posted On: 09/29/2015 2:25:18 PM
Posted this on the other board. Just random speculation as to why Leo is quiet. My conclusion is that expanding K after phase 1 is going to be expensive and will require a partner.
9/08/15 PR - 1) Cellceutix "is pleased to announce that it will be concluding its Phase 1 trial of the novel compound Kevetrin in patients
with advanced solid tumors at the completion of the current cohort."
9/08/15 PR - 2) "With the conclusion of the Phase 1 trial, clinical development of Kevetrin is going to greatly expand and accelerate"
9/08/15 PR -3) Cellceutix also wishes to inform shareholders that it is preparing a proxy statement to be filed with the Securities and Exchange Commission for the Company’s first Annual General Meeting of Shareholders.
9/17/15 BH - "My birds have been telling me of significant meetings happening (or have happened) between leo and C level execs"
9/18/15 (via Sox) Leo- "we will be fighting back with strength", "I hope to sometime next week update shareholders and you will better understand."
9/08/15 PR - 1) Cellceutix "is pleased to announce that it will be concluding its Phase 1 trial of the novel compound Kevetrin in patients
with advanced solid tumors at the completion of the current cohort."
9/08/15 PR - 2) "With the conclusion of the Phase 1 trial, clinical development of Kevetrin is going to greatly expand and accelerate"
9/08/15 PR -3) Cellceutix also wishes to inform shareholders that it is preparing a proxy statement to be filed with the Securities and Exchange Commission for the Company’s first Annual General Meeting of Shareholders.
9/17/15 BH - "My birds have been telling me of significant meetings happening (or have happened) between leo and C level execs"
9/18/15 (via Sox) Leo- "we will be fighting back with strength", "I hope to sometime next week update shareholders and you will better understand."
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼